Microbot Medical Announces Institutional Review Board Approval and Partnership with Baptist Hospital of Miami for Clinical Trial of LIBERTY Endovascular Robotic Surgical System

Microbot Medical, a clinical-stage medical device company, has secured Institutional Review Board (IRB) approval and partnered with Baptist Hospital of Miami to participate in the clinical trial of its innovative LIBERTY Endovascular Robotic Surgical System. This partnership marks the second announced site to join the trial, following the recent announcement of Brigham and Women's Hospital as another participating site. The trial aims to evaluate the effectiveness and safety of the LIBERTY system in endovascular procedures.

Key Takeaways:

• Microbot Medical has received IRB approval for its clinical trial of the LIBERTY Endovascular Robotic Surgical System, signaling progress in the development of the innovative technology.
• The company has partnered with Baptist Hospital of Miami, which will participate in the trial alongside Brigham and Women's Hospital, marking a significant milestone in the clinical evaluation of the LIBERTY system.
• Ripal Gandhi, MD, FSVM, will serve as the principal investigator at Baptist Hospital of Miami, overseeing the trial and evaluating the safety and efficacy of the LIBERTY system in endovascular procedures.
• Harel Gadot, Microbot Medical's CEO, President, and Chairman, expressed enthusiasm for the partnership with Baptist Hospital of Miami, highlighting the hospital's reputation as a leading medical institution.
• The LIBERTY Endovascular Robotic Surgical System is designed to improve the efficiency and safety of endovascular procedures by eliminating the need for large, cumbersome equipment, reducing radiation exposure, and physician strain.
• The company believes that the LIBERTY system has the potential to democratize endovascular interventional procedures, making them more accessible to patients and healthcare providers.

Statistics:

• The LIBERTY Endovascular Robotic Surgical System aims to eliminate the need for large equipment, reducing radiation exposure, and physician strain.
• The company has completed two announced sites for the clinical trial, with Baptist Hospital of Miami and Brigham and Women's Hospital participating.
• The trial will be led by Ripal Gandhi, MD, FSVM, at Baptist Hospital of Miami, with the goal of evaluating the effectiveness and safety of the LIBERTY system in endovascular procedures.

Sources:

• GlobeNewswire, "Microbot Medical Announces IRB Approval and Partnership with Baptist Hospital of Miami" (July 3, 2024)
• Microbot Medical Inc., Official Website, "About Microbot Medical" (available at )